Navigation Links
Speedy Procedures Demonstrate Excitement and Continued Interest in Novel Multi-Electrode Ablation System
Date:1/16/2008

CARLSBAD, Calif., Jan. 16 /PRNewswire/ -- Ablation Frontiers, Inc., a privately-held medical device company, announced today a successful series of catheter ablations using the company's Tip-Versatile Ablation Catheter(TM) (T-VAC). Dr. Vince Paul of the St. Peter's Hospital in Chertsey, United Kingdom is one of three leading European sites that have been evaluating this new multi-electrode linear ablation catheter since November 2007. He performed four ablation procedures for atrial flutter, a potentially dangerous irregular heart rhythm.

Diagnosed with typical atrial flutter, an arrhythmia originating from the upper chambers of the heart, the patients had all suffered from periodic episodes of palpitations, dizziness, or fatigue. "I would often get lightheaded and notice my heart was racing," said one patient who had tried several medications unsuccessfully for this "short circuit" of the heart's normal rhythm.

Performed in a cardiac catheterization laboratory, the T-VAC is inserted through a vein in the patient's leg and traversed into the heart. Dr. Paul then moved the catheter tip in the heart until he identified the precise area of cardiac tissue responsible for the irregular heart rhythm. Simultaneously applying radiofrequency (RF) energy to all six T-VAC electrodes with the Ablation Frontiers GENius(TM) RF Multi-Channel generator, Dr Paul was able to create "lesions" approximately 30mm in length. These lesions modify the cardiac tissue to block the abnormal electrical conduction. For one patient, a single ablation created in just 90 seconds completely blocked the short circuit. Another two patients required only two or three ablations to fix their arrhythmia. All four patients were successfully treated and left the Catheterization Laboratory with a normal heart rhythm.

After the final procedure of the day, which lasted 20 minutes, Dr. Paul said, "With the T-VAC and GENius generator I could create a long contiguous lesion without ha
'/>"/>

SOURCE Ablation Frontiers, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Speedy Mini-Stroke Care Pays Off
2. EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures
3. Patients need to know that nuclear medicine procedures can trigger radiation alarms
4. Non-Invasive Fat-Melting Procedures - Hype or Reality?
5. UI researchers seek to ease childrens pain during medical procedures
6. Prominent Farmington Plastic Surgeon Uses Two New Non-Surgical Procedures to Tighten Skin and Remove Fat
7. Decrease in the use of radiotherapy procedures for the treatment of cancer in hospitals
8. New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours
9. Study Shows Cosmetic Surgery on the Rise as Safety and Efficacy of Procedures Increase
10. Smoking can harm the long-term effects of some oral surgery procedures
11. UK junior doctors gaining less experience of common procedures
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers' Compensation and Leave Administration Services for Employers 2Health News:Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers' Compensation and Leave Administration Services for Employers 3Health News:Sedgwick CMS and UnitedHealth Group to Develop Integrated Disability, Medical, Workers' Compensation and Leave Administration Services for Employers 4Health News:New book presents comprehensive survey of research into the molecular basis of aging 2Health News:BBVA Chairman Francisco González announces the BBVA Frontiers of Knowledge Awards 2Health News:BBVA Chairman Francisco González announces the BBVA Frontiers of Knowledge Awards 3Health News:Fluoridated water for Queensland ... at last 2Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 2Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 3Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 4Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 5Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 6Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 7Health News:Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives 8
Breaking Medicine Technology:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Heska Announces Extension of Credit Agreement With Wells Fargo 2Heska Announces Extension of Credit Agreement With Wells Fargo 3Prodigy AutoCode Now Available in 116 Harris Teeter Pharmacies 56299 1Prodigy AutoCode Now Available in 116 Harris Teeter Pharmacies 56299 2Onyx Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 13865 1Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 1Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 2Stand Up for Health Care 21 A Labor Day Message From RWDSU President Stuart Appelbaum 56294 3
Other Medicine Technology:Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 2Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 3Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 4Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma 5Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 3Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 4Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 5